EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Pharmacomicrobiomics

Naomi Gronich iD, Naama Geva-Zatorsky iD, Rachel Herren, Libusha Kelly iD, Ziv Cohen, Haiying Zhou, Yi-Ching Chen, Khalid Shah, Talin A Robinson-Catala, Grecia Frisby, Jason H Karnes iD, Lisl Shoda iD

Clinical Pharmacology & Therapeutics · 2025-12 · 118 (6) · 1366-1377

DOI: 10.1002/cpt.70066 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 28.09.2025. Verfasst von Naomi Gronich und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Clalit Health Services, Haifa, Israel. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral medications encounter gut commensal microbes that participate directly and indirectly in drug effects through metabolism, interactions with drug metabolites, or production of substrates that compete with drugs for drug‐metabolizing enzymes, consequently influencing drug pharmacokinetics. The microbiota can also affect drug efficacy or toxicity by modulating the immune system; for example, variability in response to cancer immunotherapy, such as anti‐PD‐1 and anti‐CTLA‐4 therapies, is increasingly attributed to differences in gut microbial composition and function. These conditions indicate the need and opportunity to intentionally leverage the microbiome for drug effect; as such, the study of how intra‐ and inter‐individual differences in the microbiome affect drug response has gained a definition termed pharmacomicrobiomics. While the need is clear, clinical studies evaluating pharmacomicrobiomic interactions are challenging due to microbiome variability, multiple potential confounders, no standardization of statistical and bioinformatics methods, and the reluctance of potential clinical study participants. In this review, we make the case for pharmacomicrobiomic clinical studies; for the use of modeling and simulation to provide a quantitative framework for data integration, hypothesis testing, and translational‐to‐late‐stage clinical predictions; and the application of real‐world data to support both using a within‐subject comparison approach. We argue that an integrated and cohesive approach can address the large “inherent” inter‐individual variability in the microbiome, attributed to factors such as age, lifestyle choices, environmental factors, chemical and biological exposures, and disease. In summary, there are many challenges to pharmacomicrobiomics research but also enormous potential to improve the development and utilization of pharmaceutical products.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeHumansPharmaceutical PreparationsAnimalsModels, Biological

Substanzen

Pharmaceutical Preparations

Autor:innen und Institutionen

  • Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Clalit Health Services, Haifa, Israel.
  • Department of Emergency Medicine, Lady Davis Carmel Medical Center, Clalit Health Services, Haifa, Israel.
  • The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
  • The Ruth and Bruce Rappaport Cancer Research Center (RTICC), Technion-Israel Institute of Technology, Haifa, Israel.
  • CIFAR Humans & The Microbiome Program, CIFAR, Toronto, Ontario, Canada.
  • Department of Systems and Computational Biology, Albert Einstein College of Medicine, Bronx, New York, USA.

ORCID-Profile: Naomi Gronich, Naama Geva-Zatorsky, Libusha Kelly, Jason H Karnes, Lisl Shoda

Zitieren

APA

Gronich, N., Geva-Zatorsky, N., Herren, R., Kelly, L., Cohen, Z., Zhou, H., Chen, Y. C., Shah, K., Robinson-Catala, T. A., Frisby, G., Karnes, J. H., & Shoda, L. (2025). Pharmacomicrobiomics. Clinical Pharmacology & Therapeutics, 118(6), 1366-1377. https://doi.org/10.1002/cpt.70066

Vancouver

Gronich N, Geva-Zatorsky N, Herren R, Kelly L, Cohen Z, Zhou H, et al. Pharmacomicrobiomics. Clinical Pharmacology & Therapeutics. 2025;118(6):1366-1377. doi:10.1002/cpt.70066

BibTeX
@article{Gronich2025,
  author = {Gronich, Naomi and Geva-Zatorsky, Naama and Herren, Rachel and Kelly, Libusha and Cohen, Ziv and Zhou, Haiying and Chen, Yi-Ching and Shah, Khalid and Robinson-Catala, Talin A and Frisby, Grecia and Karnes, Jason H and Shoda, Lisl},
  title = {Pharmacomicrobiomics},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {118},
  number = {6},
  pages = {1366--1377},
  doi = {10.1002/cpt.70066}
}
Kostenlos starten →